Cosmos Health (COSM) announced that it is projecting Cur18b to generate over $2.5M in incremental annual revenue in the United States within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COSM:
- Cosmos Health announces planned U.S. market launch of Cur18b
- Cosmos Health reports FY25 adjusted EPS (12c) vs. (65c) last year
- Cosmos Health reports ‘no impact’ from Iran, MiddleEast conflict
- Cosmos Health announces planned Q2 U.S. launch of Liv18
- Cosmos Health says to issue updated guidance following FY25 results